Abbott Laboratories
ABT
$92.48
+0.85%
Abbott Laboratories is a diversified global healthcare company operating in the Medical Devices industry, manufacturing and marketing a broad portfolio including cardiovascular and diabetes devices, diagnostic equipment, nutritional products, and branded generic drugs. The company is a market leader with a distinct competitive identity built on a century-long legacy, global scale—deriving roughly 60% of sales internationally—and a balanced portfolio that provides resilience across economic cycles. The current investor narrative is dominated by a significant stock price decline following a cut to its 2026 profit guidance, which has overshadowed a recent earnings beat and sparked debate over near-term headwinds versus its long-term fundamentals, dividend growth streak, and strategic acquisition of Exact Sciences.…
ABT
Abbott Laboratories
$92.48
Related headlines
Investment Opinion: Should I buy ABT Today?
Rating & Thesis: Hold. Abbott Laboratories presents a high-conviction long-term story clouded by near-term uncertainty, making it unsuitable for new buyers until evidence emerges that the guidance cut is an isolated event, but also too oversold and fundamentally sound for existing holders to sell. The reiterated bullish stances from major analysts provide a anchor for this view, suggesting the long-term target upside remains significant once the dust settles.
Supporting Evidence: The forward P/E of 15.96x is compelling for a company of Abbott's quality and represents a 52% discount to its trailing multiple, implying the market expects an earnings rebound. The company's financial fortress—$7.4B TTM FCF, 0.29 Debt/Equity, 1.58 Current Ratio—provides a massive margin of safety and funds both the reliable dividend (54-year growth streak) and strategic growth. Furthermore, the stock trades just 3.1% above its 52-week low, indicating most negative news is likely priced in, and its diversified portfolio drove 4.4% revenue growth even in a challenging quarter.
Risks & Conditions: The two biggest risks are further guidance reductions and a failure to stabilize operating margins above 19%. This Hold rating would upgrade to a Buy if: 1) The stock establishes a firm base above the $93.92 low and shows positive momentum, or 2) Q2 2026 results demonstrate margin stabilization and reaffirm full-year guidance. It would downgrade to a Sell if: 1) Revenue growth decelerates below 3% YoY, or 2) The stock decisively breaks below $93 support on high volume. Currently, the stock is fairly valued relative to its near-term challenges but undervalued relative to its long-term fundamentals, creating a stalemate best addressed with a Hold stance.
Sign up to view all
ABT 12-Month Price Forecast
The AI assessment is neutral based on opposing high-quality signals. The severe technical breakdown and growth guidance cut are major red flags that warrant caution. However, the collapse has created a compelling forward valuation for a company with Abbott's financial strength, profitability, and analyst support. The stance hinges on the next 1-2 quarters proving the guidance cut was a one-time reset. An upgrade to bullish would require evidence of growth re-acceleration and margin stability in upcoming reports. A downgrade to bearish would be triggered by a break below $93.92 support or another guidance reduction. The high free cash flow and low debt act as a powerful downside buffer, limiting the bear case probability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $120.22 and implied upside of +30.0% versus the current price.
Average Target
$120.22
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$74 - $120
Analyst target range
Analyst coverage for Abbott appears limited in the provided dataset, with only 3 analysts contributing to estimates for EPS and revenue, indicating insufficient data to determine a clear consensus recommendation, target price, or Buy/Hold/Sell distribution. This limited coverage could imply that Abbott, despite its large market cap, may have less frequent institutional updates in this dataset, or that coverage is concentrated among a few firms; the implications include potentially higher volatility and less efficient price discovery compared to heavily covered mega-cap peers. The available institutional ratings data shows a pattern of reiterated bullish stances from major firms like Citigroup, Barclays, and RBC Capital throughout January and February 2026, with actions consistently being 'Buy', 'Overweight', or 'Outperform', suggesting that despite the stock's decline and guidance cut, analyst sentiment remains fundamentally positive on the long-term story.
Bulls vs Bears: ABT Investment Factors
The investment debate for Abbott Laboratories is a classic clash between deteriorating near-term sentiment and robust long-term fundamentals. Currently, the bear case holds stronger evidence, as the severe price decline, negative momentum, and profit guidance cut are concrete, recent events that have demonstrably shaken investor confidence. However, the bull case is supported by deeply oversold conditions, a compelling forward valuation, and unwavering analyst support for the long-term story. The single most important tension is whether the 2026 guidance cut represents a temporary setback in an otherwise sound growth plan, or the beginning of a more protracted period of earnings disappointment. The resolution of this question—visible in upcoming quarterly margins and management commentary—will determine if the stock is a value trap or a value opportunity.
Bullish
- Strong Financial Health & Cash Flow: Abbott generates substantial free cash flow ($7.4B TTM) and maintains a fortress balance sheet with a low debt-to-equity ratio of 0.29 and a current ratio of 1.58. This financial strength supports its 54-year dividend growth streak, strategic M&A like Exact Sciences, and provides resilience during downturns.
- Attractive Forward Valuation After Sell-off: The stock's sharp 26% decline has compressed its forward P/E to 15.96x, a significant discount to its trailing P/E of 33.55x. This suggests the market has priced in near-term headwinds, creating a potential value entry point for a company with a 15.5% net margin and 57% gross margin.
- Analyst Sentiment Remains Bullish: Despite the guidance cut and price decline, major institutions like Citigroup, Barclays, and RBC Capital reiterated 'Buy' or 'Overweight' ratings in early 2026. This indicates professional conviction in the long-term thesis, viewing the sell-off as an overreaction to temporary challenges.
- Oversold Technical Condition: The stock trades just 3.1% above its 52-week low of $93.92 and is down 30% from its 52-week high, indicating deeply oversold conditions. The severe negative relative strength (-18.1 vs. S&P 500 over 1 month) often precedes a technical bounce or reversal when fundamentals stabilize.
Bearish
- Profit Guidance Cut Sparks Growth Fears: The recent reduction of 2026 profit guidance, which overshadowed a Q1 earnings beat, is the primary catalyst for the stock's collapse. This signals to investors that near-term headwinds—potentially integration costs from Exact Sciences or margin pressure—are more severe than anticipated.
- Severe Negative Momentum & Underperformance: ABT has dramatically underperformed the market, down 20.5% over 3 months while the S&P 500 gained 2.67%, resulting in a -23.2 relative strength reading. This persistent selling pressure and lack of positive momentum suggest investor confidence is severely damaged and may not recover quickly.
- Trailing Valuation Remains Elevated: Despite the drop, the trailing P/E of 33.55x and EV/EBITDA of 19.51x suggest the stock still trades at a premium to many mature healthcare peers. This leaves room for further multiple compression if growth decelerates further or if the sector undergoes a derating.
- Revenue Growth Shows Sequential Deceleration: While Q4 revenue grew 4.4% YoY, the multi-quarter trend shows a slowdown from higher rates earlier in 2025. This deceleration, in the context of the guidance cut, raises questions about the near-term growth trajectory of its core Medical Devices segment ($5.68B in latest data).
ABT Technical Analysis
The prevailing price trend for Abbott Laboratories is a pronounced and sustained downtrend, with the stock down 26.09% over the past year. The current price of $96.81 sits near the bottom of its 52-week range, trading at approximately 21% above the 52-week low of $93.92 and 30% below the high of $139.06, indicating the stock is in deeply oversold territory and may represent a value opportunity, though it also signals significant negative momentum and investor pessimism. Recent momentum remains sharply negative and aligns with the longer-term downtrend, with the stock down 10.77% over the past month and 20.49% over the past three months; this persistent weakness is starkly contrasted by the S&P 500's positive performance over the same periods, resulting in severe relative strength readings of -18.13 (1-month) and -23.16 (3-month). Key technical support is clearly defined at the 52-week low of $93.92, while resistance lies at the recent trading range high near the 52-week peak of $139.06; a decisive breakdown below $93.92 would signal a continuation of the bearish trend, whereas a sustained move above the downtrend line could indicate a potential reversal, though the stock's high relative volatility versus the market (implied by its severe underperformance) suggests elevated risk for position sizing.
Beta
0.78
0.78x market volatility
Max Drawdown
-33.6%
Largest decline past year
52-Week Range
$91-$139
Price range past year
Annual Return
-28.8%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | -11.1% | +8.5% |
| 3m | -13.9% | +2.8% |
| 6m | -27.1% | +4.6% |
| 1y | -28.8% | +32.3% |
| ytd | -25.5% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Abbott's revenue trajectory shows modest but steady growth, with Q4 2025 revenue of $11.46 billion representing a 4.4% year-over-year increase; however, the multi-quarter trend reveals a sequential deceleration from higher growth rates earlier in the year, with Medical Devices ($5.68 billion in the latest segment data) likely being the primary growth driver while Nutritional Products ($1.94 billion) and Established Pharmaceuticals ($1.38 billion) provide stability. The company remains solidly profitable with a Q4 2025 net income of $1.78 billion and a robust gross margin of 57.05%, though margins have shown some compression from the prior-year period's elevated levels due to a one-time tax benefit; the operating margin of 19.64% and net margin of 15.50% indicate strong operational efficiency. Abbott's balance sheet and cash flow position are exceptionally healthy, featuring a low debt-to-equity ratio of 0.29, a strong current ratio of 1.58, and substantial free cash flow generation of $7.40 billion on a TTM basis, which amply covers its dividend payments and provides internal funding for growth initiatives and strategic acquisitions.
Quarterly Revenue
$11.5B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given Abbott's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock currently trades at a trailing PE of 33.55x, which is significantly higher than the forward PE of 15.96x; this wide gap implies the market expects a substantial recovery in earnings growth, likely anticipating a rebound from recent headwinds and the integration of the Exact Sciences acquisition. Compared to sector averages, Abbott's trailing PE of 33.55x and Price-to-Sales (PS) ratio of 4.94x are not directly comparable without a provided industry average, but its EV/EBITDA of 19.51x suggests a premium valuation relative to many mature healthcare peers, which may be justified by its superior profitability metrics like a 55.51% gross margin and its market-leading positions in key segments. Historically, the current trailing PE of 33.55x is above the stock's own recent historical range observed in the data (e.g., 5.31x in Q4 2024, 30.81x in Q4 2025), though the anomalous low in Q4 2024 was due to a one-time tax benefit; trading near the higher end of its normalized band suggests the market is still pricing in relatively optimistic long-term expectations despite the recent guidance cut and price decline.
PE
33.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Abbott's primary financial risk is not solvency—its balance sheet is strong—but rather earnings volatility and margin pressure. The guidance cut explicitly highlights near-term profit headwinds, which could stem from integration costs of the Exact Sciences acquisition, pricing pressure in medical devices, or rising input costs. While revenue growth remains positive at 4.4% YoY, any further deceleration would challenge a valuation still predicated on premium profitability (15.5% net margin) and stable growth. The company's 60% international sales exposure also introduces foreign exchange and geopolitical volatility not fully reflected in recent US-centric market turmoil.
Market & Competitive Risks: The stock faces significant valuation compression risk. Despite the drop, its trailing P/E of 33.55x and EV/EBITDA of 19.51x likely command a premium to the healthcare sector, particularly for a company that just cut guidance. If growth stock multiples contract broadly or if the market rotates away from healthcare, ABT's premium could erode further. Competitively, its core Medical Devices segment operates in innovation-driven markets (e.g., glucose monitoring, structural heart) where technological disruption is constant. The stock's severe underperformance versus the S&P 500 (relative strength -23.2 over 3 months) indicates it is being treated as a company-specific problem, amplifying its sensitivity to any further negative news.
Worst-Case Scenario: The worst-case scenario involves the 2026 guidance cut being the first of several, as integration of Exact Sciences proves more costly and disruptive than expected, while core device markets see intensified competition that pressures pricing and market share. This could lead to a prolonged period of sub-5% revenue growth and margin contraction, triggering multiple derating towards a market-average P/E for slow-growth medtech. In this adverse scenario, the stock could realistically re-test and break its 52-week low of $93.92, implying a further -3% downside from current levels, and potentially fall towards the $85-$90 range if sentiment sours further, representing a total downside of -12% to -20% from the current price of $96.81.
FAQ
The key risks are, in order of severity: 1) Execution Risk: The recent profit guidance cut indicates potential for further earnings misses or margin pressure, especially related to integrating the Exact Sciences acquisition. 2) Valuation Compression: With a trailing P/E of 33.55x, the stock could see further multiple derating if growth slows permanently. 3) Competitive & Market Risk: Intense competition in medical devices and diagnostics could pressure pricing, while its 60% international sales expose it to FX and geopolitical volatility. 4) Sentiment Risk: The stock's severe underperformance (-23.2 relative strength vs. S&P 500 over 3 months) shows damaged investor confidence, which can become a self-fulfilling prophecy and delay a recovery.
The 12-month forecast for ABT is a wide range reflecting high uncertainty, with a base case target of $105-$120 (50% probability). This assumes the company meets its revised 2026 guidance and the stock's multiple stabilizes. The bull case (30% probability) sees a rally to $130-$139 on successful execution and restored growth, while the bear case (20% probability) could see a drop to $85-$94 if guidance is cut again. The most likely scenario is the base case, hinging on the critical assumption that management's current guidance is accurate and executable. The wide forecast range underscores the binary nature of the current investment debate surrounding near-term execution.
ABT's valuation sends mixed signals, making it fairly valued in the context of its current challenges. Its trailing P/E of 33.55x appears elevated and suggests overvaluation if growth stalls. However, its forward P/E of 15.96x implies the market expects a sharp earnings recovery and appears undervalued for a company of its quality. The EV/EBITDA of 19.51x also suggests a premium to peers. The valuation disconnect indicates the market is paying a fair price for near-term uncertainty but a discount for long-term normalized earnings power. It is not egregiously overvalued or deeply undervalued; it is in a state of transition, with the forward multiple pricing in a significant margin of safety if execution improves.
ABT is a contentious buy at present. For new money, it is not a clear-cut good buy due to the unresolved near-term headwinds signaled by its profit guidance cut and severe negative momentum. However, for patient, long-term investors, the current price near a 52-week low and a forward P/E of 15.96x may represent a compelling entry point for a company with Abbott's financial strength (0.29 Debt/Equity, $7.4B FCF) and 54-year dividend growth history. It is a good buy only for those with a multi-year horizon who believe the guidance issue is temporary, and who are prepared for potential further volatility. The 30% probability bull case offers significant upside to the $130-$139 range if the thesis plays out.
ABT is unequivocally suitable only for long-term investment at this juncture. Its high volatility (evidenced by a 30% drawdown from its 52-week high), current lack of positive momentum, and unresolved fundamental questions make it a poor candidate for short-term trading. The investment thesis is based on the company's century-long legacy, diversified portfolio, and financial resilience playing out over years, not quarters. Its 54-year dividend growth streak also caters to income investors with long time horizons. A minimum holding period of 3-5 years is suggested to allow for the integration of Exact Sciences, a potential recovery in growth, and for the market to re-assess the story beyond the current negative news cycle.
